Atyr Pharma, Inc.

The Scripps Research Institute

Luke Burman

David J King

Leslie Ann Greene

Ryan Andrew Adams

Zhiwen Xu

Yanyan Geng

Kristina Hamel

Ann Menefee

Kaitlyn Rauch

Liting Zhai

Leslie Nangle Greene

Yeeting Chong

Yee Ting (Esther) Chong

Gerald M Edelman

Vincent P Mauro

Provided are affinity matured and humanized antibodies and antigen-binding fragments thereof that specifically bind to human neuropilin-2 (NRP2) polypeptides, including those that modulate binding interactions between human NRP2 and at least one NRP2 ligand, and which thereby modulate subsequent NRP2-mediated downstream signaling events, including related therapeutic compositions and methods for modulating NRP2 activity and treating diseases such as NRP2-associated diseases.

Compositions comprising anti-NRP2 antibodies

Provided are antibodies and antigen-binding fragments thereof that specifically bind to human neuropilin-2 (NRP2) polypeptides, including those that modulate binding interactions between human NRP2 and at least one NRP2 ligand, for example, human histidyl-tRNA synthetase (HRS), and which thereby modulate subsequent NRP2-mediated downstream signaling events, including related therapeutic compositions and methods for modulating NRP2 activity and treating diseases such as NRP2-associated diseases.

Compositions and methods comprising anti-NRP2 antibodies

Therapeutic compositions comprising anti-NRP2 antibodies

Provided herein is a synthetic or isolated polynucleotide encoding a mammalian 18S rRNA that is resistant to pactamycin. The pactamycin-resistance is conferred by one or more single residue substitutions in the 18S rRNA sequence; a fragment thereof harboring said substitutions; a complementary sequence thereto; or a substantially identical sequence of the foregoing. Related systems, methods and kits are also described.

Ribosomal polynucleotides and related expression systems

Growing community of inventors

San Diego, CA, United States of America

Luke Burman